MSB gave us to believe they were setting up to commercialize Rem-L themselves for paediatric sr-a-GVHD (ex Japan).
After FDA knockback they continued to display confidence they would win on appeal.
Novartis deal granted Novartis the option to take on licence for Rem-L treatment of GVHD worldwide (ex Japan).
No announcement as yet that Novartis have exercised this option. No doubt discussions ongoing.
In recent wide ranging interview SI announced the possibilty of MSB itself commercializing Rex-L for LBP in the US.
We can make the case:
That discussions with Novartis re GVHD (leave aside ARDS and CHF) are promising.
The team established to commercialize Ryoncil for GVHD is therefore being considered for Rex-L / LBP in the US.
Implies confidence on many fronts.
MSB gave us to believe they were setting up to commercialize...
-
- There are more pages in this discussion • 88 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
-0.055(5.16%) |
Mkt cap ! $1.153B | |||
| Open | High | Low | Value | Volume |
| $1.04 | $1.04 | $1.00 | $1.647M | 1.614M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 49809 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 41224 | 19 |
View Market Depth
| Last trade - 11.44am 04/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |